The Multidisciplinary Team

||Patient Story more

Prostate cancer: Mr.Chen; Malaysiamore than 1 year

Stomach Cancer: LEE YING NHOR; Malaysiamore than 1 year

Non-Hodgkin Lymphoma: Yoo Khee Chai; Malaysiamore than 1 year

||Cancer Typemore

||MDT Team more

: Chief Expert of Oncology Department; Chief physician

: Director of Oncology Department, Director of Breast Cancer Center; Associate Chief Physician

: Director of Oncology Department; Associate Chief Physician

: Deputy Director, International Oncology Ward; Attending Physician

: Chief doctor; Attending Doctor

||Medical Guidelines

11.Making an Appointment (phone, web, email)
22.Arriving at the local branch office for a free remote consultations
33.Local branch office assisting visa application
44.Arriving in the hospital for treatment
55.MDT team making a treatment plan
66.Accepting treatment for cancer
77.Treatment finish and patient discharged
88.Demanding for return visit and follow-up by local branch office

Ma Xiaoying

Views：136
2025-06-10
Share

Director of Oncology DepartmentAssociate Chief Physician: Associate Chief Physician; Specialty: more than 20 years experience of clinical work in oncology，specializes in chemotherapy, endocrine therapy, molecular targeted therapy and immunotherapy for various malignant tumors , including digesti...

Reserve

| Personal Profile

Revolutionizing Cancer Treatment with Precision Minimally Invasive Techniques: Bridging Healthcare Between China and Southeast Asia

------ A Dialogue with International Minimally Invasive Oncology Expert from Modern Cancer Hospital Guangzhou

The Path of Medical Exploration: Alleviating Suffering Through Precision Minimally Invasive Techniques

“Medicine is not just about curing diseases; it’s an art that concerns the quality of life.” — Director Ma Xiaoying

As an internationally renowned minimally invasive oncology expert and member of the China Anti-Cancer Association’s Committees for Medical Oncology and Endoscopic Oncology, Director Ma Xiaoying has dedicated over two decades to oncology diagnosis and treatment, having treated more than 5,000 patients from Southeast Asia.

Remaining true to her original aspirations, Director Ma has continuously pushed boundaries in clinical practice. She has profound expertise in chemotherapy, endocrine therapy, molecular targeted therapy, and immunotherapy for solid tumors such as gastrointestinal cancers, breast cancer, lung cancer, gynecological tumors, and urogenital tumors. She specializes in minimally invasive comprehensive treatments for advanced and refractory cancers. Her team has successfully performed over 1,000 minimally invasive surgeries, significantly extending the survival of late-stage cancer patients by more than five years. Balancing therapeutic efficacy with reduced patient suffering and prolonged survival has been the cornerstone of her clinical philosophy.

Having witnessed China’s transition in cancer treatment from traditional models to precision-oriented and minimally invasive approaches, Director Ma Xiaoying noted: “The global oncology field has entered an era of ‘integrative medicine’.” The integration of minimally invasive techniques, targeted therapies, and immunotherapy offers new hope to patients with advanced-stage disease.

Minimally Invasive Technology: Maximizing Efficacy with Minimal Trauma

Director Ma emphasizes that while traditional surgery remains a standard approach, its invasiveness can deter patients who are unfit for such procedures. She has devoted herself to advancing minimally invasive techniques such as radioactive seed implantation, interventional therapy, nanoknife ablation, and photodynamic therapy. These methods offer faster recovery and renewed hope for patients deemed “untreatable”.

When asked about the most challenging cancers to treat, Director Ma identifies advanced pancreatic and cholangiocarcinoma. However, she highlights revolutionary breakthroughs through combined minimally invasive therapies. Clinical studies show that integrated minimally invasive treatments not only control tumors effectively but also improve survival and quality of life for late-stage patients. For example, combining interventional embolization with nanoknife ablation achieves complete tumor inactivation in liver cancer or colorectal liver metastasis cases. Similarly, interventional therapy combined with localized iodine seed implantation offers breakthroughs for inoperable pancreatic cancer.

Real Cases: Anti-Cancer Miracles from Vietnamese Patients

The clinical results of precise minimally invasive treatment are not only reflected in medical research, but also in patients who have successfully fought cancer. Director Ma Xiaoying and her team have treated countless patients from Southeast Asia, among which the anti-cancer stories of ĐẶNG THỊ LEN and VÕ VĂN HOA from Vietnam fully prove the breakthrough effect of minimally invasive comprehensive treatment.

DANG THI LEN (cholangiocarcinoma) developed jaundice, loss of appetite, rapid weight loss, and extreme physical weakness due to tumor compression when diagnosed six years ago. The complex condition was considered challenging, with local hospital estimating her survival period to be 3-6 months. However, after receiving comprehensive treatment combining seed implantation, interventional therapy, and photodynamic therapy at Modern Cancer Hospital Guangzhou, the tumor was effectively controlled. She has remained recurrence-free for six years and achieved "clinical cure" status.

ĐẶNG THỊ LEN’s Pre- and Post-Treatment CT Scans

VÕ VĂN HOA (hepatocellular carcinoma) experienced low-grade fever, dull pain in the right upper abdomen, headaches, and facial nerve involvement with numbness and pain in the jaw and lips due to chronic fatigue. Diagnosed with massive hepatocellular carcinoma in 2019, he declined conventional surgery at local hospitals and instead underwent minimally invasive treatment combining interventional therapy and nanoknife at Modern Cancer Hospital Guangzhou. The original 70*60mm tumor became completely necrotic with no viable residual tissue. He has remained recurrence-free for six years and resumed normal daily life.

VÕ VĂN HOA’s Pre- and Post-Treatment CT Scans

“Precision minimally invasive therapy aims not only to eradicate tumors but to ensure patients truly benefit and enjoy high-quality survival,” Director Ma emphasizes. “Comprehensive management—from pain control and nutritional support to psychological care—is critical to outcomes.”

Academic Excellence: Pioneering Research in Tumor Immunotherapy Safety

Beyond clinical practice, Director Ma has published extensively in authoritative journals and presented at international conferences.

Her paper A Case of Sintilimab-Induced SJS/TEN: Dermatologic Adverse Reactions Associated with PD-1 Inhibitors (published in MED SCI) provides vital insights into immunotherapy safety. The study underscores the importance of multidisciplinary collaboration, standardized monitoring, and personalized interventions to mitigate risks.

The paper, combined with clinical cases, explores personalized side effect management strategies and highlights that standardized comprehensive monitoring, MDT (multidisciplinary team collaboration), and integrated interventions are critical for mitigating immunotherapy risks and enhancing patients’ quality of life. Additionally, Director Ma Xiaoying emphasized that neglecting timely attention to and intervention for adverse reactions may exacerbate disease progression or even threaten survival. Therefore, our institution has established a systematic patient monitoring framework—"pre-treatment assessment, in-treatment monitoring, and post-treatment follow-up"—alongside individualized intervention plans tailored to each patient. This approach is pivotal for ensuring both the safety and maximal therapeutic efficacy of cancer immunotherapy.

From Technology Export to Standard Co-Creation: China’s Minimally Invasive Breakthrough on the Global Stage

As a leading expert in China’s minimally invasive tumor therapy, Director Ma Xiaoying’s influence extends far beyond national borders. She has been invited multiple times to top-tier medical institutions such as the Bangkok Cancer Center in Thailand and the National University Hospital Singapore for technical exchanges. Through live surgical demonstrations, multidisciplinary consultations, and collaborative research, she has showcased the precision and efficacy of China’s minimally invasive technologies to international peers. “During a liver tumor ablation demonstration in Thailand, local physicians marveled at the nanoknife’s accuracy in controlling tumor margins, which directly catalyzed subsequent Sino-Thai collaborations in minimally invasive medicine,” she recalled.

These cross-border initiatives have not only facilitated the adoption of technologies like argon-helium cryoablation and seed implantation across Southeast Asia but also advanced international recognition of China’s minimally invasive treatment standards. At the Asia-Pacific Interventional Oncology Conference in Singapore, Ma Xiaoying’s proposed “Comprehensive Management Pathway for Advanced Tumor Minimally Invasive Therapy” was incorporated into the diagnostic and treatment guidelines of multiple Southeast Asian countries. “Our goal is not unilateral technology export, but co-building a medical system tailored to Asian populations,” she emphasized.

Today, she leads her team in collaborating with hospitals across Thailand, Vietnam, Malaysia, and Indonesia to establish a “Cross-Border Multidisciplinary Collaboration System.” Through teleconsultations, physician training, and the development of technical standardization manuals, this initiative systematically elevates cancer care standards in Southeast Asia. "When an Indonesian doctor shared that they successfully treated multiple pancreatic and cholangiocarcinoma cases using our seed implantation techniques, I became even more convinced: the value of China’s medical innovation lies in sharing hope."

From Director Ma Xiaoying, we witness the boundless potential of precision minimally invasive therapy and the profound responsibility and dedication inherent to her role as a physician. Through her innovations in tumor minimally invasive technology, academic research, and borderless medical initiatives, she has ignited hope for cancer patients worldwide. Moving forward, she will continue leveraging precision minimally invasive techniques as a bridge connecting China and Southeast Asia, ensuring that "China’s treatment protocols" emerge as a vital force in the global fight against cancer.

| Expert Publications

　　Clinical Observation of Argon-Helium Cryoablation Combined with FOLFIRI Regimen for Postoperative Liver Metastases of Colorectal Cancer

　Authors: Ma Xiaoying, Pang Anneng, Wang Zenghai, Xiao Aili

　Source: China Practical Medicine, 2016, Vol. 28, pp. 66-67

　 【Abstract】Objective To evaluate the efficacy and safety of argon-helium cryoablation combined with FOLFIRI chemotherapy in treating postoperative liver metastases of colorectal cancer. Conclusion The combined knife demonstrated superior efficacy compared to chemotherapy alone, confirming its clinical value and safety.

　　Short-Term Efficacy and Safety Analysis of PD-1 Inhibitor Combined with Anlotinib, Paclitaxel, and Cisplatin in Advanced Esophageal Cancer

　Authors: Ma Xiaoying, Zhai Xueli, Tan Shishu, Wang Xiang

　Source: Chinese Journal of Modern Drug Application, 2021, Vol. 9, pp. 155-157

　 【Abstract】Objective To assess the short-term efficacy and safety of PD-1 inhibitor combined with anlotinib, paclitaxel, and cisplatin in advanced esophageal cancer. Conclusion The PD-1 inhibitor combined with anlotinib, paclitaxel, and cisplatin demonstrates favorable disease control rates in advanced esophageal cancer, with manageable adverse effects. This regimen offers a novel therapeutic strategy for clinical practice.

　　Short-Term Efficacy Observation of Anti-PD-1 Inhibitor Combined with Anlotinib in Advanced Esophageal Cancer

　Author: Ma Xiaoying

　Source: China Practical Medicine, 2021, Vol. 36, pp. 126-128

　 【Abstract】Objective To evaluate the short-term efficacy and safety of anti-PD-1 inhibitor combined with anlotinib in advanced esophageal cancer. Conclusion The combination therapy exhibited robust disease control and tolerability, providing a promising new approach for clinical application.

| Typical Cases: